Black-box medicine is taking over. Here’s an alternative.
The increasing application of black-box models gives rise to a range of both ethical and scientific questions.
Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases with explainable AI.
The two companies aim to have a rapid target screening application available this year, enabling Contera Pharma to advance better nucleic acid-based therapeutics.